News coverage about Global Blood Therapeutics (NASDAQ:GBT) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.3518086390165 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Global Blood Therapeutics Inc (GBT) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- William Blair Initiates Coverage on Global Blood Therapeutics (GBT) (americanbankingnews.com)
- Global Blood Therapeutics (GBT) Upgraded at ValuEngine (americanbankingnews.com)
- Global Blood Therapeutics (GBT) PT Set at $73.00 by HC Wainwright (americanbankingnews.com)
GBT has been the topic of a number of recent analyst reports. Needham & Company LLC raised their price target on shares of Global Blood Therapeutics from $51.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, December 14th. HC Wainwright set a $73.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Thursday, January 11th. BidaskClub downgraded shares of Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 20th. Oppenheimer set a $79.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 12th. Finally, Nomura raised their price target on shares of Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $70.69.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.22). analysts expect that Global Blood Therapeutics will post -3.72 EPS for the current year.
In related news, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $52.85, for a total value of $158,550.00. Following the transaction, the insider now owns 137,255 shares of the company’s stock, valued at $7,253,926.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Peter Radovich sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $60.00, for a total transaction of $1,800,000.00. Following the completion of the transaction, the insider now directly owns 33,581 shares in the company, valued at approximately $2,014,860. The disclosure for this sale can be found here. In the last three months, insiders sold 54,911 shares of company stock worth $3,112,352. 5.30% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/04/01/global-blood-therapeutics-gbt-receiving-somewhat-favorable-media-coverage-accern-reports.html.
About Global Blood Therapeutics
Global Blood Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase 3 clinical trials in adult and adolescent patients with sickle cell disease (SCD), as well as in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD.
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.